ES2760699T3 - Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación - Google Patents

Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación Download PDF

Info

Publication number
ES2760699T3
ES2760699T3 ES16736381T ES16736381T ES2760699T3 ES 2760699 T3 ES2760699 T3 ES 2760699T3 ES 16736381 T ES16736381 T ES 16736381T ES 16736381 T ES16736381 T ES 16736381T ES 2760699 T3 ES2760699 T3 ES 2760699T3
Authority
ES
Spain
Prior art keywords
salmonella
protein
seq
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16736381T
Other languages
English (en)
Spanish (es)
Inventor
Heinz Lubenau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaximm AG
Original Assignee
Vaximm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaximm AG filed Critical Vaximm AG
Application granted granted Critical
Publication of ES2760699T3 publication Critical patent/ES2760699T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/001168—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ES16736381T 2015-06-18 2016-06-16 Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación Active ES2760699T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15001803 2015-06-18
PCT/EP2016/001004 WO2016202459A1 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Publications (1)

Publication Number Publication Date
ES2760699T3 true ES2760699T3 (es) 2020-05-14

Family

ID=53476620

Family Applications (2)

Application Number Title Priority Date Filing Date
ES16736381T Active ES2760699T3 (es) 2015-06-18 2016-06-16 Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
ES19205420T Active ES2994561T3 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19205420T Active ES2994561T3 (en) 2015-06-18 2016-06-16 Vegfr-2 targeting dna vaccine for combination therapy

Country Status (19)

Country Link
US (2) US10905752B2 (enExample)
EP (2) EP3626262B1 (enExample)
JP (1) JP6947649B2 (enExample)
KR (2) KR20180037948A (enExample)
CN (1) CN107995868B (enExample)
AU (1) AU2016278588B2 (enExample)
BR (1) BR112017027378A2 (enExample)
CA (1) CA2989247C (enExample)
DK (1) DK3310379T3 (enExample)
ES (2) ES2760699T3 (enExample)
HU (1) HUE046631T2 (enExample)
IL (1) IL256076A (enExample)
LT (1) LT3310379T (enExample)
MX (1) MX2017016183A (enExample)
PL (2) PL3310379T3 (enExample)
RU (1) RU2018101722A (enExample)
SI (1) SI3310379T1 (enExample)
WO (1) WO2016202459A1 (enExample)
ZA (1) ZA201708439B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005212A (es) * 2016-11-04 2019-06-20 Vaximm Ag Vacuna de adn dirigida a wt1 para terapia de combinacion.
JP7712060B2 (ja) * 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
CA3056807A1 (en) * 2017-03-17 2018-09-20 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
KR20210058825A (ko) * 2018-09-05 2021-05-24 백심 아게 병용 요법용 신생항원 표적화 dna 백신
KR20220128638A (ko) 2020-01-13 2022-09-21 백심 아게 항생제와 조합되는 살모넬라-기반의 dna 백신
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094410B2 (en) 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
NO337687B1 (no) 2011-07-08 2016-06-06 Norsk Elektro Optikk As Hyperspektralt kamera og metode for å ta opp hyperspektrale data
JP6251179B2 (ja) * 2011-12-22 2017-12-20 バクシム アクチェンゲゼルシャフト 弱毒化サルモネラ株を高収量で生産する方法
WO2014005683A1 (en) * 2012-07-05 2014-01-09 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
PT2897620T (pt) * 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
WO2014127917A1 (en) * 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
SI2988762T1 (sl) * 2013-04-25 2018-10-30 Vaximm Ag Vektorji na osnovi salmonele za imunoterapijo raka, usmerjeno v Wilmsov tumorski gen WT1
JP6662787B2 (ja) * 2013-12-18 2020-03-11 バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン
JP7712060B2 (ja) * 2017-02-17 2025-07-23 バクシム アクチェンゲゼルシャフト 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
CA3056807A1 (en) * 2017-03-17 2018-09-20 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy

Also Published As

Publication number Publication date
KR20250024816A (ko) 2025-02-19
EP3626262B1 (en) 2024-10-23
US20210077605A1 (en) 2021-03-18
RU2018101722A3 (enExample) 2019-12-10
MX2017016183A (es) 2018-06-19
SI3310379T1 (sl) 2020-02-28
CN107995868A (zh) 2018-05-04
EP3310379B1 (en) 2019-11-06
AU2016278588B2 (en) 2022-03-31
IL256076A (en) 2018-01-31
JP2018517419A (ja) 2018-07-05
WO2016202459A1 (en) 2016-12-22
CA2989247C (en) 2023-10-17
HK1252435A1 (en) 2019-05-24
US20180250345A1 (en) 2018-09-06
PL3310379T3 (pl) 2020-03-31
ZA201708439B (en) 2021-05-26
CA2989247A1 (en) 2016-12-22
US10905752B2 (en) 2021-02-02
RU2018101722A (ru) 2019-07-18
AU2016278588A1 (en) 2017-12-21
JP6947649B2 (ja) 2021-10-13
PL3626262T3 (pl) 2025-02-17
EP3310379A1 (en) 2018-04-25
EP3626262A1 (en) 2020-03-25
EP3626262C0 (en) 2024-10-23
KR20180037948A (ko) 2018-04-13
CN107995868B (zh) 2021-07-13
DK3310379T3 (da) 2019-12-16
BR112017027378A2 (pt) 2018-08-28
ES2994561T3 (en) 2025-01-27
HUE046631T2 (hu) 2020-03-30
LT3310379T (lt) 2019-12-27

Similar Documents

Publication Publication Date Title
ES2747772T3 (es) Vacuna de ADN dirigida a MSLN para la inmunoterapia del cáncer
ES2752141T3 (es) Vacuna de ADN para uso en pacientes con cáncer de páncreas
US20210077605A1 (en) Vegfr-2 targeting dna vaccine for combination therapy
US20220273782A1 (en) Novel PD-L1 Targeting DNA Vaccine for Cancer Immunotherapy
JP2023160838A (ja) 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ
US20230158133A1 (en) Wt1 targeting dna vaccine for combination therapy
HK40026195A (en) Vegfr-2 targeting dna vaccine for combination therapy
HK40026195B (en) Vegfr-2 targeting dna vaccine for combination therapy
HK1252435B (en) Vegfr-2 targeting dna vaccine for combination therapy
US20230121528A1 (en) Salmonella-based dna vaccines in combination with an antibiotic